Product Description
Mechanisms of Action: TOP2 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intramuscular,Intravenous,Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Australia | Bangladesh | Brazil | Chile | Colombia | Dominican Republic | Egypt | France | Germany | India | Ireland | Italy | Jordan | Korea | Mexico | New Zealand | Pakistan | Peru | Portugal | Russia | Saudi Arabia | Singapore | South Africa | Sri Lanka | Taiwan | Turkey | Ukraine | United Arab Emirates | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Julio Ramirez
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 1: Osteomyelitis
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
PRESTO:Osteo | P1 |
Terminated |
Osteomyelitis |
2018-11-07 |